New insights into the role of oxidative stress in scleroderma fibrosis

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 87-95

  Gabrielli, Armando ^a   Svegliati, Silvia ^a   Moroncini, Gianluca ^a   Amico, Donatella ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Fibrosis; Free radicals; Systemic sclerosis

Indexed keywords

CASPASE; FREE RADICAL; NITRIC OXIDE SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA;

DISEASE ASSOCIATION; DNA DAMAGE; FIBROSIS; HUMAN; KIDNEY FIBROSIS; LIPID PEROXIDATION; LIVER FIBROSIS; LUNG FIBROSIS; MEMBRANE DAMAGE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS; UPREGULATION;

EID: 84863913123     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010087     Document Type: Review

References (89)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Murrel DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993, 28: 78-85.
3. Halliwell B. Reactive oxygen species in living systems: source, biochemistry and role in human disease. Am J Med 1991; 91: 145-225.
4. Halliwell B, Gutteridge JMC. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990; 280: 1-8.
5. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human diseases. Int J Biochem Cell Biol 2007; 39: 44-84.
6. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 1988; 255: H1269-75.
7. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Eur J Physiol 2010; 459: 923-39.
8. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-9.
9. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-6.
10. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia 2000; 43: 1435-8.
11. Higashi Y, Sasaki S, Nakagawa K, et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002; 15: 326-32.
12. Los M, Schenk H, Hexel K, Baeuerle PA, Schulze-Osthoff K. IL-2 gene expression and NF-kB activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J 1995; 14: 3731-40.
13. Feng XLY, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cycloxygenase-2 expression induced by interleukin-1 tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 1995; 95: 1669-75.
14. Berard K, Krause K-H. The nox family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87, 245-313.
15. Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res 2006; 71: 289-99.
16. Hayashi T, Stetler SWG, Fleming MV, et al. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol 1996, 149: 1241-56.
17. McKeown S, Richter AG, O'Kane C, McAuley DF, Thickett DR. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J 2009; 33: 77-84.
18. Nelson KK, Melendez IA. Mitochondrial redox control of matrix metalloprotenases. Free Radic Biol Med 2004; 37: 768-84.
19. Mates JM, Segura JA, Alonso FJ, Marquez J. Intracellular redox status and oxidative stress: implication for cell proliferation, apoptosis and carcinogenesis. Arch Toxical 2008; 82: 273-99.
20. Fattman CL. Aportosis in pulmonary fibrosis: too much or not enough? Antioxid Redox Signal 2008; 10: 379-85.
21. Wang X, Martindale JL, Liu Y, Holbrook NJ. The cellular response to oxidative stress: influences of mitogen activated protein kinase signalling pathways on cell survival. Biochem J 1998; 333; 291-300.
22. Pande V, Ramos MJ. Molecular recognition of 15-deoxydelta (12,14)-prostaglandin J (2) by nuclear factor-kappa B and other cellular proteins. Bioorg Med Chem Lett 2005; 15: 4057-63.
23. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337-40.
24. Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxiainducible factor-1 alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 2000; 275: 25130-8.
25. Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo MR, Avvedimento EV. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis reviseted. Semin Immunopathol 2008; 30: 329-37.
26. Ogawa F, Shimizu K, Muroi E, Hara T, Sato S. Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol 2011; 30: 921-5.
27. Ogawa F, Shimizu K, Hara T, et al. Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxidereductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Arch Dermatol Res 2010; 302: 27-35.
28. Avouac J, Borderie D, Ekindjian OG, Kahan A, Aleanore Y. High DNA oxidative damage in systemic sclerosis. J Rheumatol 2010; 37: 2540-7.
29. Svegliati S. Svegliati S, Cancello R, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005; 280(43): 36474-82.
30. Aden N, Shiwen X, Aden D, et al. Proteomic analysis of scleroderma lesional skin reveals activated wound phenotype of epidermal cell layer. Rheumatology 2008; 47: 1754-60.
31. Dooley A, Shi-Wen X, Aden N, et al. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology 2010; 49(11): 2024-36.
32. Dooley A, Low SY, Holmes A, et al. Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosis. Rheumatology 2008; 47: 272-80.
33. Oberly LW, Buettner GR. The production of hydroxyl radicals by bleomycin and iron (II). FEBS Lett 1979; 97: 47-9
34. Teixeira KC, Soares FS, Rocha LG, et al. Attenuation of bleomycin-induced lung injury and oxidative stress by Nacetylcysteine plus deferoxamine. Pulm Pharmacol Ther 2008; 21: 309-16.
35. Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K. Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 1999; 113: 843-7.
36. Yoshizaki A, Yanaba K, Ogawa A, et al. The specific free radical scavenger edaravone suppresses fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2011; 63: 3086-97.
37. Manoury B, Nenan S, Leclerc O, et al. The absence of reactive oxygen species production protects mice against bleomycininduced pulmonary fibrosis. Respir Res 2005 21; 6: 11.
38. Servettaz A, Goulvestre C, Kavian N, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 2009; 182: 5855-64
39. Kavian N, Servettaz A, Mongaret C, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum 2010; 62: 3477-87.
40. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum1995; 38: 1060-7.
41. Cracowski JL, Kom GD, Salvat-Melis M, et al. Postocclusive reactive hyperemia inversely correlates with urinary 15-F2tisoprostane levels in systemic sclerosis. Free Radic Biol Med 2006; 40: 1732-7
42. Sambo P, Jannino L, Candela M, et al. Monocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999; 112: 78-84.
43. Thannickal VJ, Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem 1995; 270: 30334-8
44. Albright CD, Salganik RI, Craciunescu CN, Mar MH, Zeisel SH. Mitochondrial and microsomal derived reactive oxygen species mediate apoptosis induced by transforming growth factor-beta1 in immortalized rat hepatocytes. J Cell Biochem 2003; 89: 254-61
45. Peltoniemi M, Kaarteenaho-Wiik R, Säily M, et al. Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-beta in vitro and in interstitial lung diseases in vivo. Hum Pathol 2004; 35: 1000-7
46. Islam KN, Kayanoki Y, Kaneto H, et al. TGF-beta1 triggers oxidative modifications and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Free Radic Biol Med 1997; 22: 1007-17.
47. Lassègue B, Sorescu D, Szöcs K, et al. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88: 888-94.
48. Datla SR, Peshavariya H, Dusting GJ, Mahadev K, Goldstein BJ, Jiang F. Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol 2007; 27: 2319-24.
49. Jobling MF, Mott JD, Finnegan MT, et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res 2006; 166: 839-48
50. Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factorbeta1 in hypertensive rats. Mol Cell Biochem 2008; 317: 43-50.
51. Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005; 97(9): 900-7.
52. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15: 1077-81.
53. Rhyu DY, Yang Y, Ha H, et al. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005; 16: 667-75.
54. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-76.
55. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345(7): 517-25.
56. Kelly C Teixeira, Fernanda S Soares, LuÃ-s GCR, et al. Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Pulm Pharmacol Ther 2008; 21(2): 309-16.
57. Manoury B, Nenan S, Leclerc O, et al. The absence of reactive oxygen species production protects mice against bleomycininduced pulmonary fibrosis. Respir Res 2005; 6: 11.
58. Bowler RP, Nicks M, Warnick K, Crapo JD. Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002; 282(4): L719-26.
59. Fattman CL, Chang LY, Termin TA, Petersen L, Enghild JJ, Oury TD. Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismutase. Free Radic Biol Med 2003; 35(7): 763-71.
60. Montuschi P, Ciabattoni G, Paredi P, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998; 158(5 Pt 1): 1524-7.
61. Psathakis K, Mermigkis D, Papatheodorou G, et al. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur J Clin Invest 2006; 36(5): 362-7.
62. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163(7): 1693-722.
63. Kanoh S, Kobayashi H, Motoyoshi K. Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest 2005; 128(4): 2387-92.
64. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139(2): 370-2.
65. Kinnula VL, Hodgson UA, Lakari EK, et al. Extracellular superoxide dismutase has a highly specific localization in idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology 2006; 49(1): 66-74.
66. Daniil ZD, Papageorgiou E, Koutsokera A, et al. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2008; 21(1): 26-31.
67. Lakari E, Soini Y, Säily M, Koistinen P, Pääkkö P, Kinnula VL. Inducible nitric oxide synthase, but not xanthine oxidase, is highly expressed in interstitial pneumonias and granulomatous diseases of human lung. Am J Clin Pathol 2002; 117(1): 132-42.
68. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161(2 Pt 1): 646-64.
69. Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133(1): 226-32.
70. Bocchino M, Agnese S, Fagone E, et al. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblast in idiopathic lung fibrosis. PLoS One 2010; 5: e14003.
71. Behr J. Oxidant and antioxidants in idiopathic pulmonary fibrosis. In: Lynch JP, Ed. Idiopathic pulmonary fibrosis. New York: Marcel Dekker 2004; pp. 379-96.
72. Shukla A, Ramos-Nino M, Mossman B. Cell signaling and transcription factor activation by asbestos in lung injury and disease. Int J Biochem Cell Biol 2003; 35(8): 1198-209.
73. Selman M, Pardo A. Matrix metalloproteinases and tissue inhibitors of metallo-proteinases in pulmonary fibrosis. In: Linch JP, Ed. Idiopathic pulmonary fibrosis. New York: Marcel Dekker 2004; pp. 451-81.
74. Tan RJ, Fattman CL, Niehouse LM, et al. Matrix metalloproteinases promote inflammation and fibrosis in asbestosinduced lung injury in mice. Am J Respir Cell Mol Biol 2006; 35(3): 289-97.
75. Meyer A, Buhl R, Magnussen H. The effect of oral Nacetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7(3): 431-6.
76. Demedts M, Behr J, Buhl R, et al. IFIGENIA Study Group. Highdose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-42.
77. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 1988; 34(1): 77-82.
78. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2285-7.
79. Denton CP, Bunce TD, Dorado MB, et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology 1999; 38(4): 309-15.
80. Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 1979; 38(4): 356-61.
81. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells. Hepatology 2006; 44(6): 1487-501.
82. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115(2): 209-18.
83. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008; 19(3): 593-9.
84. Thomas M, Gavrila D, McCormick ML, et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006; 114(5): 404-13.
85. Sugiyama H, Kobayashi M, Wang DH, et al. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 2005; 20(12): 2670-80.
86. Okamura DM, López-Guisa JM, Koelsch K, Collins S, Eddy AA. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol 2007; 293(2): F575-85.
87. Okamura DM, Pennathur S, Pasichnyk K, et al. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol 2009; 20(3): 495-505.
88. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13(10): 1176-84.
89. Haddad JJ. Oxygen-sensing mechanisms and the regulation of redox-responsive transcription factors in development and pathophysiology. Respir Res 2002; 3: 26-52.